Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, single-arm, observational study to evaluate the tolerability and efficacy of carfilzomib-based therapy for antibody mediated rejection in adult patients with lung transplant recipients

Trial Profile

A single-center, single-arm, observational study to evaluate the tolerability and efficacy of carfilzomib-based therapy for antibody mediated rejection in adult patients with lung transplant recipients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Lung transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Apr 2017 Results (n=19) presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 07 Feb 2017 Results (n=14) assessing effect of carfilzomib on antibody mediated rejection of the pulmonary allografts, published in the American Journal of Transplantation
    • 30 Apr 2016 Results (n=16) assessing the impact of pre-treatment donor specific HLA antibody titer on the carfilzomib-based therapy efficacy presented at the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top